US Proposal Could Halve Biocon’s Biosimilar Development Costs

India’s Biocon expects a 50% drop in costs for developing complex biosimilars as the United States has proposed to ease clinical testing for the drugs that make up more than 60% of its revenue, a top executive said on Wednesday.

More From Author

<div>Hardik Pandya’s Return Date Confirmed? Report Makes Big Claim</div>

India A vs South Africa A 1st Unofficial ODI Highlights: Ruturaj Gaikwad Century Helps India A Win By 4 Wickets

Leave a Reply